HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

rimonabant

a potent & selective antagonist of the brain cannabinoid receptor; structure given in first source

Also Known As:

Acomplia; N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride; SR 141716; SR 141716A; SR-141716A; SR141716; SR141716A; Sanofi-Synthelabo brand of rimonabant; Zimulti

Networked: 673 relevant articles (91 outcomes, 152 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Azoles: 413
    - Pyrazoles: 26
      - rimonabant: 673
  - Piperidines: 12
    - rimonabant: 673

Experts

1.	Després, Jean-Pierre: 11 articles (07/2011 - 11/2005)
2.	Bifulco, Maurizio: 10 articles (06/2015 - 10/2004)
3.	Kim, Jeongmin: 10 articles (02/2010 - 04/2008)
4.	Lee, Jinhwa: 10 articles (02/2010 - 04/2008)
5.	Lee, Sung-Han: 10 articles (02/2010 - 04/2008)
6.	Di Marzo, Vincenzo: 9 articles (11/2013 - 12/2002)
7.	Seo, Hee Jeong: 9 articles (02/2010 - 04/2008)
8.	Scheen, André J: 9 articles (02/2009 - 04/2005)
9.	Laezza, Chiara: 8 articles (06/2015 - 10/2004)
10.	Jung, Myung Eun: 8 articles (02/2010 - 04/2008)

Related Diseases

1.	Obesity 04/01/2008 - "However, given the efficacy of this treatment and the magnitude of the obesity problem, rimonabant may prove to be a valuable adjunct in targeting obesity-related cardiovascular risk factors." 05/01/2012 - "They have been explored and found to be effective as therapeutic agents for obesity and related cardiometabolic problems; however, use of rimonabant, the first marketed CB(1) receptor antagonist, has been suspended because of its anxiogenic and depressogenic side effects. " 04/01/2005 - "In humans, rimonabant appears to be effective for treatment of obesity and smoking cessation. " 05/01/2007 - "Is rimonabant a safe and effective treatment for obesity?" 06/01/2004 - "Rimonabant was shown to be safe and effective in treating the combined cardiovascular risk factors of smoking and obesity. "
2.	Weight Loss (Weight Reduction) 01/01/2014 - "Central CB1R antagonists, notably rimonabant, induced weight loss and improved the metabolic profile in obese individuals, but were discontinued due to psychiatric side-effects. " 10/01/2009 - "Rimonabant resulted in a significantly greater benefit than placebo for all primary weight loss outcomes. " 07/01/2008 - "Weight loss from baseline to 2 years in the intention-to-treat population was significantly greater with rimonabant 20 mg (mean +/- SD: -5.5 +/- 7.7 kg; P < 0.001) and 5 mg (-2.9 +/- 6.5 kg; P = 0.002) than placebo (-1.2 +/- 6.8 kg). " 04/01/2008 - "Moreover, it has been shown that the agent rimonabant, which was first used in order to achieve weight reduction, also contributed to the significant improvement of metabolic syndrome's parameters. " 11/11/2006 - "Weight loss was significantly greater after 1 year in both rimonabant groups than in the placebo group (placebo: -1.4 kg [SD 3.6]; 5 mg/day: -2.3 kg [4.2], p=0.01 vs placebo; 20 mg/day: -5.3 kg [5.2], p<0.0001 vs placebo). "
3.	Body Weight (Weight, Body) 02/01/2013 - "These results provide proof of principle that combination of rimonabant and a MCH1 receptor antagonist is highly effective in reducing body weight below that achieved by rimonabant and SNAP-94847 monotherapies. " 02/01/2013 - "Combining sub-threshold doses of rimonabant and SNAP-94847 produced a significantly greater loss of body weight in DIO mice compared with vehicle and monotherapies. " 02/01/2010 - "On all three diets, rimonabant treatment improved metabolic derangements and led to significantly lower body weight gain than their respective controls. " 08/01/2013 - "NESS06SM reduces body weight with an improved profile relative to SR141716A." 02/01/2011 - "In all the trials, there was a considerable reduction in body weight in subjects taking 20 mg rimonabant daily varying from 2.6 to 6.3 kg (placebo-subtracted changes). "
4.	Insulin Resistance 03/01/2012 - "Treatment with SR141716 significantly improved insulin resistance and lipid abnormalities. " 07/01/2013 - "Our data might indicate that a lower dose of rimonabant in the treatment of insulin resistance and type 2 diabetes is sufficient to administer, thus a lower incidence of the unfavorable psychiatric side effects of rimonabant are to be expected. " 01/16/2009 - "Interestingly, the rimonabant-treated adipo(-/-)ob/ob mice also exhibited significant amelioration of insulin resistance, although the degree of improvement was significantly lower as compared with that in the ob/ob mice. " 03/01/2012 - "Therefore, we examined the effect of the cannabinoid (CB)1 receptor antagonist, SR141716, on insulin resistance and diabetic nephropathy in db/db mice. " 07/01/2008 - "Rimonabant is shown in the current issue of British Journal of Pharmacology to attenuate weight gain in Zucker rats, an experimental model of insulin resistance. "
5.	Overweight 01/01/2006 - "In four randomised, double-blind clinical trials in overweight or obese adults with or without type 2 diabetes and/or dyslipidaemia, oral rimonabant 20mg once daily reduced weight and waist circumference to a significantly greater extent than placebo. " 03/01/2007 - "Rimonabant, a selective CB(1) antagonist, is a novel treatment option for obese and overweight individuals. " 08/01/2010 - "This study sought to identify the effect of drug reimbursability--a decision made in France by the National Authority for Health--on physicians' prescribing practices for a diet drug such as rimonabant, approved for obese or overweight patients with type-2 diabetes. " 11/11/2006 - "Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study." 08/23/2006 - "[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]."

Related Drugs and Biologics

1.	CB1 Cannabinoid Receptor (CB1 Receptor)
2.	Glucose (Dextrose)
3.	Triglycerides (Triacylglycerol)
4.	HDL Cholesterol
5.	rimonabant
6.	Endocannabinoids (Endocannabinoid)
7.	Insulin (Novolin)
8.	Cholesterol
9.	Cannabinoid Receptors (Cannabinoid Receptor)
10.	Lipids

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Caloric Restriction
3.	Self Administration (Administration, Self)
4.	Ganglionectomy
5.	Vagotomy